Ranking by Regions
United States
Canada
Mexico
Brazil
Chile
Germany
United Kingdom
France
Spain
Netherlands
Sweden
Italy
Switzerland
Poland
Finland
China
Japan
South Korea
Hong Kong
Singapore
Indonesia
India
Malaysia
Taiwan
Thailand
Australia
New Zealand
Israel
Saudi Arabia
Turkey
Russia
South AfricaRanking by categories
As of January 22, 2025, Siegfried Holding (SFZN.SW) has a market cap of $4.84 billion USD. According to our data, Siegfried Holding is ranked No.2724 in global market value.
| Year | Market Cap | %Change |
|---|---|---|
| Jan 22, 2025 | $4.84 B |
2.43%
|
| Dec 30, 2024 | $4.73 B |
15.19%
|
| Dec 29, 2023 | $4.10 B |
40.10%
|
| Dec 30, 2022 | $2.93 B |
-30.67%
|
| Dec 30, 2021 | $4.22 B |
36.99%
|
| Dec 30, 2020 | $3.08 B |
39.81%
|
| Dec 30, 2019 | $2.21 B |
40.56%
|
| Dec 28, 2018 | $1.57 B |
4.44%
|
| Dec 29, 2017 | $1.50 B |
53.22%
|
| Dec 30, 2016 | $0.98 B |
9.89%
|
| Dec 30, 2015 | $0.89 B |
21.98%
|
| Dec 30, 2014 | $0.73 B |
1.15%
|
| Dec 30, 2013 | $0.72 B |
42.79%
|
| Dec 28, 2012 | $0.51 B |
28.67%
|
| Dec 30, 2011 | $0.39 B |
-0.83%
|
| Dec 30, 2010 | $0.40 B |
-3.21%
|
| Dec 31, 2009 | $0.41 B |
6.47%
|
| Dec 31, 2008 | $0.39 B |
-51.51%
|
| Dec 31, 2007 | $0.79 B |
7.86%
|
| Dec 29, 2006 | $0.74 B |
13.55%
|
| Dec 30, 2005 | $0.65 B |
19.30%
|
| Dec 31, 2004 | $0.54 B |
-6.79%
|
| Dec 31, 2003 | $0.58 B |
4.33%
|
| Dec 31, 2002 | $0.56 B |
16.67%
|
| Dec 31, 2001 | $0.48 B |
-10.01%
|
| Dec 29, 2000 | $0.53 B |
9.56%
|
| Dec 31, 1999 | $0.49 B |
-9.25%
|
| Dec 31, 1998 | $0.54 B |
-13.65%
|
| Dec 31, 1997 | $0.62 B |
44.49%
|
| Dec 31, 1996 | $0.43 B |
40.46%
|
| Dec 29, 1995 | $0.31 B |
100%
|
| Name | Market Cap | Market cap difference | Regions |
|---|---|---|---|
 Eli Lilly
LLY
|
$676.92 B |
0.020 M
|
USA
|
 Novo Nordisk A/S
NOVO-B.CO
|
$365.09 B |
95.523 B
|
Denmark
|
 Johnson & Johnson
JNJ
|
$347.78 B |
-0.005 M
|
USA
|
 Novo Nordisk
NVO
|
$335.53 B |
64.154 B
|
Denmark
|
 AbbVie
ABBV
|
$300.53 B |
0.002 M
|
USA
|
 Roche
ROG.SW
|
$243.91 B |
38.073 B
|
Switzerland
|
 Merck
MRK
|
$242.59 B |
0.007 M
|
USA
|
 Thermo Fisher Scientific
TMO
|
$220.26 B |
-0.000 M
|
USA
|
 AstraZeneca
AZN
|
$211.43 B |
0.005 M
|
UK
|
 Novartis
NVS
|
$197.43 B |
0.007 M
|
Switzerland
|
 Pfizer
PFE
|
$148.34 B |
-0.006 M
|
USA
|
 Amgen
AMGN
|
$147.53 B |
0.002 M
|
USA
|
 Sanofi
SNY
|
$128.55 B |
0.003 M
|
France
|
 Gilead Sciences
GILD
|
$116.07 B |
0.004 M
|
USA
|
 Bristol-Myers Squibb
BMY
|
$115.86 B |
0.003 M
|
USA
|
 Vertex Pharmaceuticals
VRTX
|
$110.70 B |
-0.001 M
|
USA
|
 CSL
CSL.AX
|
$82.06 B |
-0.963 B
|
Australia
|
 Regeneron Pharmaceuticals
REGN
|
$75.23 B |
1.245 B
|
USA
|
 Zoetis
ZTS
|
$75.07 B |
-0.001 M
|
USA
|
 Chugai Pharmaceutical
4519.T
|
$69.96 B |
0.455 B
|
Japan
|
| Market Cap | = | SFZN.SW Stock Price | * | SFZN.SW Shares Outstanding |
| = | $1,114.93 | * | 4.34 M | |
| = | $4.84 B |